Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more
Mural Oncology plc (MURA) - Net Assets
Latest net assets as of September 2025: $55.19 Million USD
Based on the latest financial reports, Mural Oncology plc (MURA) has net assets worth $55.19 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.76 Million) and total liabilities ($10.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $55.19 Million |
| % of Total Assets | 83.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Mural Oncology plc - Net Assets Trend (2021–2024)
This chart illustrates how Mural Oncology plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mural Oncology plc (2021–2024)
The table below shows the annual net assets of Mural Oncology plc from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $140.50 Million | -46.74% |
| 2023-12-31 | $263.82 Million | +1318.22% |
| 2022-12-31 | $-21.66 Million | -21.13% |
| 2021-12-31 | $-17.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mural Oncology plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15937100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $171.00K | 0.12% |
| Other Components | $299.70 Million | 213.31% |
| Total Equity | $140.50 Million | 100.00% |
Mural Oncology plc Competitors by Market Cap
The table below lists competitors of Mural Oncology plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shapir Engineering Industry
TA:SPEN
|
$29.48 Million |
|
ALM EQUITY AB
F:I53
|
$29.48 Million |
|
Paloma Acquisition Corp I Units
NASDAQ:PALOU
|
$29.48 Million |
|
ICD Tan Cang Long Binh JSC
VN:ILB
|
$29.49 Million |
|
Van Dien Fused Magnesium Phosphate Fertilizer JSC
VN:VAF
|
$29.45 Million |
|
FERMENTALG EO -04
F:1F6
|
$29.45 Million |
|
Rein Therapeutics Inc
NASDAQ:RNTX
|
$29.44 Million |
|
Capital Small Finance Bank Limited
NSE:CAPITALSFB
|
$29.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mural Oncology plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 263,817,000 to 140,502,000, a change of -123,315,000 (-46.7%).
- Net loss of 128,514,000 reduced equity.
- New share issuances of 196,000 increased equity.
- Other factors increased equity by 5,003,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-128.51 Million | -91.47% |
| Share Issuances | $196.00K | +0.14% |
| Other Changes | $5.00 Million | +3.56% |
| Total Change | $- | -46.74% |
Book Value vs Market Value Analysis
This analysis compares Mural Oncology plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.07 | $2.04 | x |
| 2022-12-31 | $-1.30 | $2.04 | x |
| 2023-12-31 | $15.81 | $2.04 | x |
| 2024-12-31 | $8.29 | $2.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mural Oncology plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-91.47%) is below the historical average (-42.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-173.65 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-187.64 Million |
| 2023 | -78.63% | 0.00% | 0.00x | 1.14x | $-233.83 Million |
| 2024 | -91.47% | 0.00% | 0.00x | 1.21x | $-142.56 Million |
Industry Comparison
This section compares Mural Oncology plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mural Oncology plc (MURA) | $55.19 Million | 0.00% | 0.19x | $29.47 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |